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Abigail Fisk Thompson 
 
IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF YAP-TEAD 
BINDING WITHIN THE HIPPO SIGNALING PATHWAY 
 
The Hippo signaling pathway controls organ size by regulating cell proliferation, 
apoptosis, and cell differentiation. The Hippo pathway ultimately regulates the 
concentration of the coactivator yes-associated protein 1 (YAP1) in the nucleus, which 
binds the transcription factor TEA domains (TEAD), activating genes related to cell 
proliferation. In several cancers, increased YAP1 activity is linked to increased cellular 
proliferation, de-differentiation and survival to drive tumor progression and spreading. 
The development of inhibitors against YAP-TEAD binding are consequently a research 
topic of much interest. While several inhibitors of the YAP-TEAD interaction are 
reported, none possess both high specificity and anti-tumor activity. The work described 
here is based upon a collaboration with AtomWise, Inc to find a best in class competitive 
inhibitor of YAP-TEAD binding. AtomWise completed a computational screen of ten 
million compounds for potential binding to a TEAD pocket that is essential for 
interaction with YAP1. This master’s thesis encompasses both intracellular and 
biochemical validation of these compounds. Initially, a luciferase YAP/TEAD dependent 
reporter assay was used to identify compounds with potential intracellular activity. This 
data was compared with the action of these compounds on the metabolic activity (MTT 
assay) across three cancer cell lines.  Three sulfonamide-based compounds, 4, 22, and 59 
were identified as top 10 YAP/TEAD inhibitors. Six additional compounds were 
synthesized that combined specific moieties in these three compounds.  Dose response 
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curves for inhibition of TEAD reporter activity showed that compounds 22 and 59 
exhibited both high inhibition and low IC50 values relative to the derivatives. Further, 
compound 22 also significantly reduced the levels of CTGF transcript (measured by RT-
qPCR), a surrogate measure for endogenous YAP1: TEAD activity. Preliminary 
fluorescent polarization data also suggests that compound 22 inhibits the binding of a 
5(6)-FAM labeled YAP1 peptide (residues 58-74) to a purified TEAD fragment.  
In this work, compounds 22 and 59 are found to inhibit TEAD dependent 
transcription and the growth of multiple cancer cell lines. In addition, promising 
preliminary biochemical data indicates that compound 22 may inhibit the interaction of 
YAP1 with TEAD. 
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CHAPTER 1: INTRODUCTION  
 
1.1  The Hippo Pathway  
The Hippo pathway promotes cell differentiation and apoptosis while inhibiting 
cell movement and growth to influence organ size and to suppress tumor formation [1]. 
Anti-growth cues including cell stresses and cell-cell contacts activate HIPPO signaling 
[2]. Whereas, cell-extracellular matrix interactions and growth factor signaling inhibit the 
HIPPO pathway [3]. Core HIPPO signaling involves the activation of the large tumor 
suppressor (LATS) kinases via phosphorylation by the Mst1/2 kinases that occurs in 
response to upstream signals including cell-cell contacts and cell polarity [3]. Active 
LATS1/2 then phosphorylate and functionally suppress the ability of YES-associated 
protein 1 (YAP1) to activate transcription factors [4]. Phosphorylation inhibits YAP1 by 
targeting it for 14-3-3 mediated sequestration in the cytoplasm and for proteasomal 
degradation [5]. Conversely, accumulation of non-phosphorylated YAP1 in a background 
of low HIPPO signaling results in high levels of nuclear YAP1 that co-activates TEA 
domain (TEAD1-4) and other transcription factors [6]. Consequently, genes associated 
with cell proliferation and cell survival are actively transcribed (Figure 1) [7]. 
 Cell contacts and mechanical loading play oppositional roles in the regulation of 
the Hippo pathway [8-10]. Cells in tissues interact with their neighbors to form 
differentiated structures [11]. The resultant intercellular contacts promote high 
intracellular HIPPO signaling that prevents the accumulation of YAP1 in the nucleus 
[12]. Conversely, when cells have sparse contacts with other cells, the cytosolic levels of 
YAP1 increase [12]. In parallel, mechanical loading on the cell by a threshold of 
extracellular matrix (ECM) stiffness stimulates YAP1 to be imported into the nucleus [5]. 
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These findings were mainly uncovered by experiments studying cells growing in matrices 
of varying stiffness usually by altering the composition of collagen in Matrigel [13]. 
Additionally, YAP1 was shown to accumulate in the cytoplasm but not enter the nucleus 





Figure 1. Schematic representation of the Hippo Signaling Pathway. When 
phosphorylated by LATS Kinases, YAP1 is sequestered in the cytoplasm and is 
eventually degraded by ubiquitin mediated proteasomal degradation. YAP1 can enter the 
nucleus and bind TEAD when not phosphorylated, activating genes involved in cell 































1.2   Two examples of YAP1 and human disease  
The initiation and progression of many cancers are highly dependent on the 
activation of YAP1, meaning the Hippo pathway is inactive and YAP1 is 
unphosphorylated and enters the nucleus. [15]. In multiple types of solid tumors, YAP1 
levels and activity are upregulated in the tumor tissue relative to adjacent normal tissue 
[16]. A meta-analysis of 21 studies totaling 2983 patients found that the overexpression 
of YAP1 is associated with poor prognosis and reduced rates of survival across several 
types of cancer [17]. This is due to the amplification of the YAP1 gene in cancers of the 
lung, pancreas, esophagus, liver, and breast [18]. Whereas, increased transcript levels of 
YAP1 in the absence of gene amplification are observed in many other types of human 
cancer [19]. Because TEADs have been found to be essential for the pro-cancer effects of 
YAP1, the development of molecules that inhibit YAP1 binding to TEADs is an active 
area of anti-cancer research [20].  
In addition to cancer, several other diseases including autosomal dominant 
polycystic kidney disease (ADPKD) are associated with aberrant YAP1 activity [21]. 
ADPKD is the fourth leading cause for kidney transplants and kidney related deaths [22]. 
ADPKD is characterized by the spontaneous formation of fluid filled cysts in about 1 % 
of renal tubules [23]. The continuous enlargement of these cysts eventually leads to renal 
failure [24]. While mutational inactivation of Pkd1 or Pkd2, which code for polycystin 
proteins that play roles in cell-cell signaling, accounts for 85 % of ADPKD cases [25, 
26], a gene set enrichment analysis showed an enrichment of TEAD target genes, 
including c-Myc, in human polycystic kidney samples [27]. Further work showed that 
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Pkd1 inactivation results in YAP1 dephosphorylation and nuclear accumulation [28]. 
YAP1 activation is therefore proposed to drive cyst growth following Pkd1 deficiency 
[27]. Currently, kidney transplant is the only treatment for PKD [29]. A small molecular 
inhibitor of YAP1-TEAD binding could therefore delay the damage caused by cyst 
growth to increase the window for transplant before renal failure. 
 
1.3   YAP-TEAD binding interface 
Multiple crystal structures of fragments of YAP1 bound to different TEAD1, 
TEAD2, and TEAD4 to reveal three conserved binding interfaces (Figure 2) [30, 31]. 
The consensus minimal TEAD‐binding region in YAP1 comprises three sequential 
elements. The first region (residues 50-56) consists of an anti-parallel beta-sheet that 
interacts with TEAD through main chain hydrogen bonding [30]. Consistent with reports 
that these bonds contribute minimally to overall binding, deletion of residues 50-56 in 
YAP1 results in minimal differences in its binding affinity for TEAD [32]. Taken 
together, the lack of specificity of the beta sheet interface and its small energetic 
contribution to binding argues against targeting this interface to inhibit YAP1 binding to 
TEAD. The second region (residues 61-73) forms an alpha-helix that binds to a 
hydrophobic pocket in TEAD [30]. Three residues, Leu65, Leu68, and Phe69, lie along 
the alpha-helical interface that contacts TEAD to form an LxxLF motif, which is known 
to bind to hydrophobic grooves [33]. Further, Phe69 directly contacts residues within the 
TEAD hydrophobic pocket and serves as the rotation center for YAP1 (Figure 3)[34]. 
The important contribution of Phe69 for binding was affirmed by experiments showing 
that substitution with Ala increases the Kd from 18 nM in wild type YAP1 to 6447 nM 
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[35]. The identification of molecules that bind to the pocket in TEAD that binds Phe69 is 
therefore a highly attractive strategy to inhibit YAP1-TEAD binding. Region three 
(residues 85-99) comprises a twisted coil region referred to as an omega loop [30]. 
Hydrophobic side chains on residues M86, L91, and F95 in the YAP1 omega loop form 
van der Waals interactions with several hydrophobic residues within a pocket on TEAD 
that is formed by three beta strands and two alpha helices (Beta 4, 11, and 12 and alpha 1 
and 4)[36]. This interface is further strengthened by an interaction between R89 of YAP1 
and the carboxylate oxygen of an aspartate in TEAD [36]. Studies have shown that the 
omega loop interface is necessary for the efficient binding of YAP1 and TEAD [32] and 
multiple groups have targeted this interface for drug discovery. The YAP1 binding 
domain has shown to have 100% identity among the four TEADs, meaning one inhibitor 







Figure 2. Illustration of the YAP1-TEAD1 binding interfaces. TEAD2 is shown in 
grey bound to the YAP152-56 beta strand, YAP161-73 alpha helix, and YAP185-99 omega 





Figure 3. Structural representations of YAP1 alpha-helical region interaction with 
TEAD2.  Phe69 within the alpha-helical interface 2 of the YAP1-TEAD binding surface 
fits into a binding pocket on TEAD2 (depicted in left panel as a ribbon plot and in right 
panel as a surface density plot, both plots were prepared by Neil Henrikson at AtomWise 




1.4   Palmitoylation of TEAD  
The post-translational palmitoylation of a conserved cysteine in all TEAD 
members promotes their stability and potentially binding to YAP1 [37]. While the 
consensus of numerous studies is that a cysteine residue buried in a hydrophobic pocket 
in TEAD is efficiently autopalmitoylated, the effects of this modification are 
controversial. Although initial reports found that palmitoylation of TEAD is essential for 
binding to YAP1, more recent studies find that mutants that lack the autopalmitoylated 
cysteine are highly unstable [38]. Further, a cysteine to alanine TEAD mutant showed a 
complete loss of stable protein in cells [39]. Conversely, another study found that the 
palmitoylation of TEAD plays no role in its localization, but is required for binding to 
YAP1 [37]. In either case, the key role that palmitoylation plays in the stability of TEAD 
and potentially its binding to YAP1 necessitates its consideration as part of an effort to 
develop inhibitors against YAP1-TEAD binding. This has been directly addressed by 
several reports showing that small molecules that covalently bind to the conserved 
cysteine in TEAD inhibit the interaction of TEAD with YAP1. However, no studies have 
examined how palmitoylation of TEAD may impact competitive inhibitors of YAP1-
TEAD, which may explain why compounds with promising inhibitory effects in vitro 
have failed to have strong effects in vivo. 
 
1.5   Overview of previous efforts to develop inhibitors of YAP1-TEAD binding 
Peptides based on the YAP1 sequence have shown promise as competitive 
inhibitors of YAP1-TEAD binding. Therapeutic peptides are straightforward to 
synthesize and generally show high specificity for binding their target with low toxicity. 
 
 8 
A peptide containing the sequence of the flexible omega-loop in YAP1 can inhibit YAP1 
binding to TEAD with an IC50 of 37.0 µM [40]. Peptides with amino acid substitutions 
that decrease the flexibility of the omega-loop peptide and consequently increase the 
binding to TEAD, including the introduction of cysteines to cyclize the peptide via a 
disulfide bond [40], can achieve an IC50 of as low as 1.81 uM for preventing YAP1 
binding to TEAD[40]. However, it is unclear whether this peptide avoids common issues 
associated with other peptides such as metabolic instability, poor oral bioavailability, low 
cellular uptake, and rapid clearance [41].  
Small molecule approaches have also shown some promise for competitively 
inhibiting the binding of YAP1 to TEAD. However, no reported compounds have shown 
both specific anti-YAP1-TEAD activity and strong anti-tumor effects. Initially, the FDA 
approved drug verteporfin was pursued as a promising YAP1-TEAD inhibitor. 
Verteporfin is used in the clinic as a laser activated drug to remove blood vessels growing 
underneath the retina in macular degeneration [42]. Pan and colleagues subsequently 
identified Verteporfin as an inhibitor of YAP1-TEAD in a luciferase reporter assay. 
Importantly, they found that Verteporfin treatment also prevented YAP1-induced liver 
overgrowth in mice [20]. Consequent studies found that Verteporfin inhibits the growth 
of several breast cancer lines and that it is particularly effective at blocking the growth of 
breast cancer cells lines with high YAP1 expression. However, the relatively high 
concentrations of verteporfin that were needed to inhibit growth (1 -10 µM) did not 
correlate with the levels of YAP1 expression across the cell lines tested [43]. Similar 
results were found for bladder, gastric, and ovarian cancer cell lines [44-46]. In addition, 
even though verteporfin was reported 8-years ago to inhibit YAP1-TEAD, there is still no 
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structural information on how verteporfin interacts with this complex. Further, 
verteporfin has been found to exert antitumor properties through several non-HIPPO 
pathway targets. For instance, verteporfin inhibits the growth of endometrial cancers via 
its interaction with epidermal growth factor receptor (EGFR) in a YAP1-independent 
manner [47]. Verteporfin also binds to p62 to inhibit autophagy, which results in a loss of 
cell growth [48]. Verteporfin therefore appears to have a broad range of targets whose 
inhibition may result in reducing cancer cell growth that are independent of YAP1-
TEAD. These issues are compounded with other chemical limitations of verteporfin 
including its difficulty to synthesize, limited solubility and light sensitive stability. 
As previously mentioned, several groups have developed covalent inhibitors 
directed against the cysteine in TEADs that is palmitoylated. The hydrophobic pocket 
containing the palmitoylated cysteine residue is thought to stabilize TEAD and improve 
its ability to bind to YAP1 [39]. Consistently, small molecules that covalently bind this 
cysteine have shown potent inhibition of bacterially expressed TEADs binding to YAP1 
[49]. However, these compounds generally have an electrophile that can covalently 
modify the reactive cysteine trough that is buried in the hydrophobic pocket of TEADs, 
preventing the palmitoylation of TEADs. These compounds may therefore have 
significant activity to surface exposed cysteines of other proteins that they come into 
contact. Further, it is unclear whether palmitate has a high off rate from TEADs in cells 
and whether the compounds can effectively displace palmitate from a majority of 
intracellular TEADs.  
Recently, celastrol was reported to prevent YAP1-TEAD binding. Celastrol is 
isolated from the roots of the plant Celastrus regelii and has anti-obesity effects in mice. 
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In 2015, celastrol was reported to curb food intake by nearly 80 percent causing up to 45 
percent weight loss in mice tested [50] by potentially sensitizing the hunger modulating 
effects of the lepton hormone to the brain [51]. More recently, celastrol was shown to 
significantly reduce YAP1 transcriptional targets including CTGF by 65 percent. 
Celastrol also reduced the rate of proliferation and viability of H1299 lung and MDA-
MB-231 breast cancer cell lines [52]. However, when the concentration of Celastrol was 
reduced from 5 µM to 1 µM, CTGF levels were only reduced by 10 percent. While the 
anti-cancer effects of Celastrol are promising, there is no direct evidence that celastrol 
binds to TEADs. 
 
1.6   Current work on compounds predicted by AtomWise, Inc to bind the Ph69 
binding pocket in TEAD 
 AtomWise, Inc uses artificial intelligence to enhance drug discovery. AtomWise 
developed AtomNet, an algorithm that uses a deep convolutional neural network to 
improve structure-based drug discovery. Convolution neural networks break down 
complex concepts into smaller fragments of information that are analyzed in isolation and 
then pieced back together [54]. Convolution neural networks have had recent success in 
image classification, speech recognition and face recognition [54]. For example, 
convolution neural networks recognize a face by first “learning” the features of the edge 
of the face and then by putting these edges back together to establish similarities between 
larger parts of the face, including eyes, ears, and noses [54]. The system then learns how 
to combine the individual face parts to gain a high certainty for recognition of a whole 
face. AtomNet used this method to “learn” the trends and rules within organic chemistry 
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that were then combined to recognize important chemical groups that dictate interactions 
between ligand and protein interfaces [54]. AtomWise has been contracted for drug 
discovery with companies including Merck, Eli Lilly, Bayer, Abbvie, and for many 
educational research institutions though the Artificial Intelligence Molecular Screen 
(AIMS) award program. This program accepts grant applications from academic research 
institutions across the world that are interested in finding a small molecule that binds a 
specific target. Over 300 AIMS awards have been granted to a broad range of projects 
involving animal health, biotechnology, human biology, medicine, microbiology, plant 
biology, and virology. The targets of AIMS awardees are subject to a customized small 
molecule virtual screen using AtomNet technology, which screens over ten million 
compounds for binding abilities. The researcher then receives around 70 small molecules 
that are predicted to bind to the target.  
Dr. Wells and Dr. Georgiadis were awarded an AtomWise, Inc AIMS grant to 
computationally screen 10 million compounds for their likelihood to bind to the 
hydrophobic pocket of TEAD1 that binds Phe69 in YAP1. AtomWise employed their 
unique AI-directed docking algorithms to predict molecules that should bind TEAD in a 
pocket that binds Phe69 within the alpha-helical region of YAP1. From this screen, 76 
“hit” compounds were delivered. My master’s thesis carried out an intracellular and 
biochemical validation of these 76 small molecules for their ability to inhibit the binding 





CHAPTER 2: METHODS 
 
2.1   Silencing of YAP1 in HeLa Cells  
Following trypsinization, HEK-293T cells were plated and grown to 70% 
confluency in 10 cm plates. Media was then aspirated and replaced with 8 mL of serum 
free DMEM containing the PEI transfection mixture.  This transfection mixture was 
created by mixing 50 µg PEI dropwise (25 µl) into 1 mL serum free DMEM that contains 
6 µg pVSV, 5 µg pRSV-REV, 10 µg pRRE, and 20 µg shYAP. Cells were incubated 
with the transfection mixture at 37o C and 5% CO2 for 16 hours.  The media was then 
replaced with 7 mLs complete DMEM (10% fetal bovine serum) containing 10 mM 
HEPES pH 7.5. The cells were incubated for an additional 18 h at 37o C in 5 % CO2 
before the media containing virus was collected. After any cellular material was removed 
from the media by centrifugation, 27 µL of 5 mg/mL of polybrene was added per 7 mLs 
of media with virus. Viral media with polybrene was then diluted 1:3 with complete 
DMEM. After removing the media from a 10 cm plate with 30 % confluent HeLa cells, 3 
mL of diluted virus was added. After 24 hours, virus containing media was aspirated and 
replaced with complete DMEM.  At 24 hours after infection cells were split for assays 
and for measuring YAP1 silencing by immunoblot analysis.  At 48 hours of viral 
infection, 60 cm dishes of cells were harvested in 100 µL of lysis buffer (100 mM Tris 
pH 8.5, 10 mM urea, 2 mM sodium orthovanadate, and 25 mM beta-glycerol phosphate). 
Protein lysates were then analyzed by immunoblot for relative levels of YAP1 and beta-
tubulin.  Additionally, cells were reverse transfected into 24-well plates 24 hours post 
infection with the TEAD reporter and Renilla reporter constructs.  After 48 hours, these 
cells were harvested in passive lysis buffer. The firefly/Renilla luciferase activity in 20 µl 
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of lysate from each well was measured using the Duo Luciferase Genecopoeia kit (cat # 
LF001).    
shYAP1 Construct – V3875: GCCACCAAGCTAGATAAAGAA 
shScramble Construct – V3325: CCTAAGGTTAAGTCGCCCTCGCTCTAG                    
CGAGGGCGACTTAACCTTAGG 
 
2.2   Immunoblot Analysis 
Cells were washed with ice cold PBS and then detached in 1mL PBS with a 
rubber spatula.  Cells were transferred to a 1.5 mL micro centrifuge tube and collected by 
centrifugation at 5000 RPM for 5 minutes using an Eppendorf 5424. Cell pellets were 
lysed for 5 min on ice with 100 µL of  lysis buffer (50 µL 1M Tris buffer pH 8.5, 0.24 g 
Urea, 10 µL 100x ProteCEASETM protease inhibitor, 10 µL 100x sodium orthovanadate, 
100 µL 10x beta glycerol phosphate). Post nuclear supernatants were clarified by 
centrifugation at 10,000 RPM at 4o C for 5 minutes.  Clarified lysates were collected and 
stored at -80 oC or subjected to sodium-dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  For SDS-PAGE, 20 µL of lysate was added to 4µl of 6X 
sample buffer.  Samples were then denatured at 95o C for 5 minutes. Protein samples 
were then loaded using a Hamilton syringe into individual wells of a 12 % SDS 
polyacrylamide gel. Protein were resolved through gel at 150V for 90 minutes. Proteins 
were then transferred from a gel to a nitrocellulose membrane at 12V for 90 minutes 
using a GENIE electrophoretic transfer system in transfer buffer (25 mM Tris pH 7.6, 
192 mM glycine, 20 % methanol, and 0.03% SDS).   After transfer, membranes were 
blocked with 5% powdered milk in tris-buffered saline.  Blots were then washed 3X with 
Tris-buffered saline with 0.05% Tween-20 (TBST) for five minutes with rocking at room 
temperature. The membrane was then transferred into a hybridization bag and 3 mLs of  
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TBST, 1µl of a mouse anti-Beta tubulin antibody (1:3000) and 3 µl of rabbit anti-YAP1 
antibody (1:1000) was added before the bag was sealed.  The membrane was then 
incubated with the antibodies at 4o C with rocking on a nutator for 2 hours. The corner of 
the bag was then cut and the antibody mix was recovered for re-use of up to 3 times.  The 
membrane was then removed from the bag and transferred to a grey plastic box for 
washing with TBST three times for 5 minutes at room temperate on a rotary shaker.  
After removal of the last wash, 10 mLs of TBST were then added which contained a goat 
anti-mouse secondary antibody diluted 1:20,000 and a Donkey anti-Rabbit antibody 
diluted 1:20,000.  The box containing the membrane and antibodies was then covered by 
a second stackable box and it was returned to the rotary shaker for 30 minutes with 
rocking at room temperature. After washing the membrane for 3X in TBST for 5 minutes, 
the nitrocellulose membrane was imaged using a LiCor © Odyssey machine. 
 
2.3   Luciferase Reporter Assay in HeLa Cells 
The day before an assay, HeLa cells were split 1:2 so that cells would be in log 
phase growth.  The following day, cells were reverse transfected with the reporter 
construct.  For each transfection, the pGL3.1 plasmid containing the CTGF promoter 
(0.13 µg/well) and the TK Renilla (0.13 µg/well) plasmid were added to 500 µL of serum 
free DMEM. PEI (2 µg/well) was added to DNA mixture with vortexing and was 
incubated at room temperature 10 minutes. The mixture was added to non-adherent HeLa 
cells at a density of 40,000 cells per well and serum free DMEM to reach a final volume 
of 500 µL per well. The cell mixture was plated in 24 well plates and left in tissue culture 
hood to settle for 20 minutes. Cells were then incubated at 37o C and 5 % CO2 for two 
hours.  The media was aspirated off cells and replaced with compound dissolved in 
 
 15 
DMSO diluted in DMEM/10 % fetal bovine serum. Cells were incubated with compound 
for 18 hours at 37o C and 5 % CO2. Media was aspirated and cells were washed with 250 
µL PBS on ice. Cells in each well were harvested with 100 µL of passive lysis buffer and 
rocked for 15 minutes. Lysates were transferred to 1.5 mL microcentrifuge tubes and 
spun down at 14,000 RPM at 4o C for 10 minutes. 20 µL of supernatant was transferred 
to new 1.5 mL microcentrifuge tubes and the firefly luciferase activity was measured in 
ratio with the control TK renilla luciferase activity, using the GeneCopoeia Luc-Pair™ 
Duo-Luciferase Assay Kit 2.0 (cat # LF001). 
CTGF Luciferase Reporter Construct – V4088 
TK Renilla Construct – V3605 
 
 
2.4   MTT Assay  
 MIA, Pa14C, and H460 Cells were seeded at 10,000 cells per well in a 96 well 
plate in 55 µL of DMEM/10 % FBS supplemented with 3 % matrigel and incubated at 
37o C and 5% CO2. On day four, 55 uL of compounds at 40 µM were add to the cells and 
incubated for an additional four days. On day eight, 55 µL of 20 µM compound 
containing media was added. On day 12, 18 µL of 5 mg/mL MTT reagent in PBS was 
added to each well for 2 hours. 75 µL of the medium was removed and 100 µL of 16% 
SDS in 40% DMF with 2% glacial acetic acid was added to each well. The plate was 
incubated at 37o C and 5% CO2 overnight and the absorbance was measured at 570 nm 
the following day.  
 Normal kidney cells, autosomal dominant polycystic kidney disease, and adjacent 
autosomal dominant polycystic kidney disease cells were seeded at 1,000 cells per well in 
a 96 well plate. Media was aspirated after 24 hours and replaced with 100 µL of media 
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containing compound. Cells were incubated with compound for 36 hours at 37o C and 5% 
CO2. 20 µL of 5mg/mL MTT reagent in PBS was added to each well and returned to the 
incubator for 2 hours. After two hours, 100 µL of MTT solvent (4mM HCl and 0.1% 
Triton X in isopropanol) was added to each well. The plate was covered with foil and 
placed in the dark at room temperature for one hour. Absorbance of wells were measured 
at 570 nm after one hour. 
 
2.5   Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
 HeLa cells were grown in DMEM with 10% FBS to 50% confluence in 6 cm 
plates and then treated with 20 µM compound for 24 hours. The cells were washed with 1 
mL ice-cold PBS, harvested with 1 mL of Trizol, and incubated at room temperature for 
5 minutes. 100 µL of chloroform was added and the samples were spun down for 10 
minutes at 14,000 RPM at 4o C. The supernatant was transferred to new tubes and the 
RNA was precipitated out with 1 mL isopropanol. The sample was spun at 14,000 RPM 
for 10 minutes at 4o C and the supernatant was removed. The RNA was washed with 500 
µL 70% ethanol, spun down, at 14,000 RPM for 5 minutes at 4o C, and the supernatant 
was removed. The RNA pellet was dried and was resuspended in 20 µL of H2O. 5 µL of 
RNA was added to a mixture containing 10 µL H2O, 2 µL oligo dT (50 µM), and 4 µL 
dNTPs (10 mM) and incubated for 5 minutes at 65o C. Complimentary deoxyribonucleic 
acid (cDNA) synthesis was completed by incubating the RNA, oligo dT and dNTP 
mixture with 10 µL H2O, 4 µL RT Buffer, and 2 µL SuperScript reverse transcriptase. 
The samples were incubated at 50o C for 45 minutes. The DNA concentration was 
measured using the NanoDrop© spectrophotometer and samples were diluted to 400 
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ng/µL with nuclease-free water. A mixture of 5 µL of the dilute cDNA, 10 µL of H2O, 10 
µL of SYBR Green PCR SensiMix (Bioline), and 1 µL of both forward and reverse 
primers were added to wells in a 96 well plate and assayed using the RealPlex ABI-
FastOpti (Eppendorf) protocol. Values were normalized to 18S rRNA. Forward and 
reverse primers used are listed below. 
18S rRNA Forward Primer:  CCGATAACGAACGAGACTCTGG 
18S rRNA Reverse Primer:  TAGGGTAGGCACACGCTGAGCC 
CTGF Forward Primer:   CCGTACTCCCAAAATCTCCA 
CTGF Reverse Primer:   GTAATGGCAGGCACAGGTCT 
 
 
2.6   TEAD2 Expression and Purification 
The pet29a-TEAD2217-447 construct was obtained from the Guo lab at the 
University of Texas Southwestern and transformed into the Escherichia coli strain 
Rosetta (DE3) to produce an N-terminal His6-tagged TEAD2217-447. The bacteria were 
grown in terrific broth at 37o C with shaking at 225 RPM until an OD600 of about 2.0 was 
met. The bacteria were cooled on ice for 15 minutes and induced with 0.2 mM IPTG. 
Bacteria were incubated at 16o C with shaking at 225 rpm for 18 hours. Cells were 
collected with centrifugation at 14,000 rpm at 4o C for 15 minutes and resuspended in 2 
mL lysis buffer per 1 gram of bacteria pellet (500 mM NaCl, 50 mM Tris pH 7.5, 10 mM 
imidazole, 5 mM beta-mercaptoethanol). Cells suspension was passed through 
microfluidizer four times and lysates were clarified with ultracentrifugation at 35,000 
rpm at 4o C for 30 minutes, transferred to new centrifuge tubes, and spun at 35,000 RPM 
at 4o C for 10 minutes. Clarified lysate was filtered using a 0.45 µm disposable filter and 
60 mL syringe (25mm diameter, PES membrane, GE). The filtered lysate was batch 
bound with buffer equilibrated Ni-NTA agarose (Invitrogen, 0.25 mL 50% resin 
 
 18 
suspension per 50 mL lysate) with rocking on nutrator at 4o C for two hours. Lysate-resin 
mixture was poured into a BioRad column and washed with 40 mL wash buffer (500 mM 
NaCl, 50 mM Tris pH 7.5, 20 mM imidazole, 5 mM beta-mercaptoethanol) and eluted 
with 8 mL elution buffer (50 mM Tris pH 7.5, 500 mM NaCl, 300 mM imidazole, 5 mM 
beta-mercaptoethanol). Two uL of 6X sample buffer was added to 10 uL aliquots of the 
load, flow through, 20 mM imidazole wash, and elution fractions. The samples were 
boiled for 5 minutes at 95o C and loaded to a 12% acrylamide SDS gel using a Hamilton 
syringe. The gel was run at 200V for one hour. The gel was then Coomassie stained for 
visualization of proteins. Elution fractions containing TEAD2 were combined and 
dialyzed overnight using a Slide-A-Lyzer 10K dialysis cassette (Pierce) in 3 liters of QA 
buffer (20 mM Tris pH 8.5, 20 mM NaCl, 1mM DTT). Sample was loaded on an 18 mL 
Q Sepharose Fast Flow (GE Healthcare) packed column at a flow rate of 2.5 mL/minute. 
A gradient was run from 0% to 34%QB (20 mM Tris pH 8.5, 1 M NaCl, 1 mM DTT) was 
run over 17 column volumes and a gradient from 35% to 60%QB over 3 column 
volumes. Protein fractions were collected and run on a 12% acrylamide SDS gel at 200 V 
for one hour followed by Coomassie staining. TEAD2 containing fractions were diluted 
to ~20 mM NaCl and loaded to a second 18 mL Q Sepharose Fast Flow column at 2.5 
mL/minute. A gradient was run from 20%QB to 36%QB over 10 column volumes. 
Elution fractions were run on a 12% acrylamide SDS gel at 200 V for one hour followed 
by Coomassie staining. Fraction contain purified TEAD2 were combined and 
concentrated to 4 mg/mL using a 30,000 MWCO concentrator. The concentrated protein 










2.7   Coomassie Staining 
After running an SDS-PAGE gel, the gel was rinsed with water 3 times and set in 
15 mL Coomassie destaining solution (40% methanol, 10% acetic acid) for 5 minutes 
with rocking at room temperature. The destaining solution was removed. 15 mL of 
Coomassie stain (0.2% Coomassie Blue R-250, 40% methanol, 10% acetic acid) was 
added to the gel, covered with plastic wrap, and microwaved for 10 seconds. The gel was 
then rocked at room temperature for 25 minutes. Coomassie blue stain was poured off 
and the gel was rinsed three times with water. 15 mL Coomassie destain was added to the 
gel, covered in plastic wrap, and microwaved for 10 seconds. Destain was replaced with 
fresh destain and was rocked at room temperature until bands were visible and 
background is clear. Several destain solution replaces were required. The stained gel was 
imaged on light box. 
 
2.8   Fluorescence Polarization  
10 nM fluorescently labeled peptide (5(6) FAM-YAP158-74 or YAP161-99) was 
incubated with TEAD2 in binding buffer (25 mM Tris pH 8.5, 250 mM NaCl, 1 mM 
DTT, and 5% glycerol) to a final volume of 40 uL in black Costar 384-well plates at 
room temperature for one hour in the dark. If testing compound effects on binding, 
TEAD2 was treated with compound dissolved in DMSO for 30 minutes prior to the 
addition of the fluorescently labeled peptide. Excitation wavelength was 485 nm and 
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CHAPTER THREE: INTRACELLULAR RESULTS  
 
3.1   Optimization and validation of a TEAD dependent transcriptional assay 
A luciferase reporter assay was optimized as a precursor for the screening of the 
76 compounds received from AtomWise, Inc for effects on intracellular YAP1/TEAD 
activity. This assay used a pGL3.1 based reporter construct that contains a 3.1 kB 
fragment of the CTGF promoter in which the serum response elements were ablated.  
This construct was previously demonstrated by the Wells laboratory to express firefly 
luciferase in direct relation to intracellular YAP1/TEAD activity. Thus, any compounds 
that inhibit the activation of TEAD by YAP1 will reduce the expression of firefly 
luciferase.  Cells were simultaneously transfected with a Thymidine Kinase (TK) Renilla 
reniformis luciferase construct.  By normalizing luciferase activity by dividing firefly 
activity by Renilla reniformis activity, values were corrected for differences in pipetting, 
transfection efficiency, and cell density.  Compounds with off-target effects e.g. cellular 
toxicity, non-specific inhibition of transcription etc. could also be detected based upon 
their having significant effects on TK-Renilla activity.  
Initially, three cell lines were assessed for their ability to be transfected and for 
significant endogenous YAP1 activity. The three cell lines included uterine cancer cells 
(HeLa), glioblastoma cells (A172), and kidney cells (HEK293T). Basal YAP1 activity 
was inferred by degree to which the TEAD reporter assay was inhibited upon silencing of 
YAP1. Cell lines were also evaluated for their ability to be easily transfected by the 
luciferase constructs. HeLa cells were both highly transfectable and had high basal levels 
of reporter activity. Further, this activity was inhibited by over 45 % upon transduction 
with transduction lentivirus encoding shRNA against YAP1. Immunoblot analysis found 
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an ~ 90 % reduction of YAP1 levels in cells transduced with shYAP1 relative to the 
control cells. (Figure 4). The relatively low reduction in luciferase activity upon YAP1 
silencing may be due to the incomplete knockdown of YAP1 and/or the presence of other 
factors including TAZ that may also activate TEAD in HeLa cells. In order to determine 
the statistical effect size, luciferase activity was measured in 36 replicates of HeLa cells 
with YAP1 knockdown or shcontrol to calculate a z’ factor. The result of 0.540 indicates 
an excellent assay (Figure 5). 
 Transfection with polyethyleneimine (PEI) was further optimized due to the low 
cost of this method.  While the standard transfection method is performed upon cells split 
the day before, this resulted in poor efficiency for HeLa cells. However, the reverse 
transfection method, where cells are plated after splitting into media containing the PEI 
transfection mixture, achieved high levels of transfection and minimal cell death. This is 
presumably due to the ability of cells to be completely bathed in the transfection mixture 
before they adhere to the plate.  This method was also more flexible, as cells could be 






Figure 4. YAP1 dependence of the TEAD reporter assay.  (a) An illustration of the 
luciferase reporter construct with a CTGF promoter depicts that the transcription of 
firefly luciferase is dependent upon the binding of the coactivator YAP1 to the 
transcription factor TEAD. (b) An immunoblot using the anti- YAP1 antibody and B-
tubulin for a loading control demonstrates the degree of YAP1 knockdown in HeLa cells. 
(c) Luciferase activity (a ratio of firefly luciferase to TK Renilla) was measured in HeLa 












































Figure 5. The Z’ factor for the TEAD reporter assay.   HeLa cells silenced for YAP1 
or with control shRNA were plated into 36 replicates for each condition and TEAD 
reporter activity was determined. The individual activities are plotted and at right the Z’ 
factor, overall Means, and standard deviations from the Mean are given. Z’ factor was 




3.2   TEAD reporter assays and cell growth assays 
The seventy-six blind compounds received from AtomWise, Inc were then 
screened for an ability to inhibit the TEAD reporter actvity. To this end, HeLa cells were 
reverse transfected with the luciferase reporter constructs and then treated with 20 µM of 
each compound or with vehicle for 16 hours before harvesting in passive lysis buffer. 
Luciferase activities were measured in lysates and are presented as the fold-difference in 
mean normalized luciferase values for each compound versus the normalized mean 
values from HeLa cells treated with vehicle (DMSO). From this data, 11 of the 
compounds inhibited the activity of the reporter by 50 percent or greater (Figure 6). 
Compounds showing inhibition in the reporter assay are presumed to enter the cells and 
the nucleus, causing a decrease in TEAD dependent transcription. Several compounds, 























including 4 and 22, inhibited the reporter activity to a greater degree than silencing YAP1 
expression.  However, data from compounds that exerted large effects on Renilla 
luciferase activity and/or resulted in significant amounts of cell death  were omitted due 
to non-specific “denominator” effects on Renilla activity and the high intra-sample error, 
likely from the high levels of cell death.  
 In a complementary approach, Dr. Quilliam measured the effects of each 
compound on the viability of three cells lines (MIA PACA; pancreatic cancer, Pa14C; 
pancreatic cancer, and H460; lung cancer). Cell viability was determined using the MTT 
assay.  This assay measures the degree of reduced MTT in cells by NAD(P)H-dependent 
oxidoreductase enzymes.  Since NAD(P)H flux is mainly dependent on overall cellular 
metabolic activity, that, in turn, is primarily a function of cell number (assuming the 
treatments are over several days), this assay is very commonly used to measure cell 
accumulation over time. Cell viability data was combined with the TEAD luciferase 
reporter assay data in Figure 7. This highlights that while compounds 22 and 4 had the 
greatest TEAD luciferase reporter assay inhibition, they were not the most efficacious 
compounds for inhibiting cell growth.  However, compound 59 was both a top 10 
inhibitor of the TEAD reporter assay and it reduced cell growth by over 50 percent in two 
of the cell lines. In collaboration with Dr. Johnson, compounds 4, 22 and 59 were 
recognized as chemically similar sulfonamides (Figure 8).  This suggested that they may 
be members of a class of related compounds that target the YAP1-Phe69 binding pocket 
in TEAD.   Compounds 4, 22, and 59 were therefore subjected to additional biochemical 







Figure 6. Mean fold-change induced by each compound on reporter activity. The 
fold-change in activities of the luciferase reporter in cells treated with each compound 
depicted in a scatter plot (a) and a bar graph (b). HeLa cells were treated with 20 µM of 
each compound and the luciferase to TK Renilla ratio was normalized to DMSO values. 
Each compound was tested in quadruplicate. Compounds that were toxic were omitted 
from the graphs. A line was included at 1.0 to emphasize the luciferase activity of cells 
treated with DMSO as the control.   
 
 

















































Figure 7. Association of the effects of 76 compounds on TEAD reporter activity and 
on cell viability. TEAD luciferase reporter assay data and cell viability data were 
combined into one heat map. The TEAD reporter assay data is normalized luciferase 
activity and the MIA, Pa14C, and H460 Lung cell viability data is in percent cell 









Figure 8. Structural comparison of compounds 4, 22 and 59.  The similar structures, 
of Compounds 4, 22, and 59, (all are top 10 inhibitors of the TEAD reporter assay) are 





3.3   Structural relationships and derivatives of compounds 4, 22, and 59 
 The structural relationship of compounds 4, 22, and 59 to their activities were 
then probed.  Compounds 4 and 59 have nearly identical substituents on one side of the 
sulfonamide core, but 4, 22 and 59 have varying phenyl groups on the other side. Analogs 




















Compound 4 Compound 22 Compound 59
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contain different combinations of substituents in compounds 22 and 59 (Figure 9). These 
compounds were tested for inhibition of the TEAD reporter assay. Because compound 
1989 had greater inhibition than compound 59, the aromatic-ether may inhibit binding to 
TEAD.  While compounds 1993, 1994, and 1995 which contain the three ring structure of 
22 had comparable levels of inhibition to compound 59 (Figure 10). The chemical 
moieties in 22 and 50 on the right side of the sulfonamide backbone may therefore bind 
similarly to TEAD.  
 
 
Figure 9. Structural depiction of second generation analogs. The structures of second 
generation analogs are shown alongside the structures of their parent compounds 4, 22 


































































Figure 10. Mean fold-change induced by analog compounds on reporter activity. 
The mean fold-change of luciferase activity as a ratio of firefly luciferase to TK Renilla 
was measured in HeLa cells treated with 20 µM of the analogs and compounds 22, 4, and 
59. The luciferase activity was normalized to signal of cells treated with DMSO. 
Compounds were tested in quadruplicate. The line at 1.0 emphasizes the luciferase 
activity of the control cells treated with DMSO.  
 
 
3.4   Dose response of compounds in TEAD reporter assays 
 Dose response curves were obtained for the effects of compounds 4, 22, and 59 on 
TEAD reporter activity. Cells were treated with each compounds at concentrations from 
0.3 to 30 µM in 3-fold increments.  Data were then fit to nonlinear regression curves for 
the concentration of inhibitor vs. response with four parameters in Prism (GraphPad Inc.). 
IC50 values were then obtained using Prism for each compound. Compound 22 had the 
lowest IC50 value of 1.08 µM, followed by compounds 4 and 59, which had IC50 values 
of 1.74 µM and 2.8 µM, respectively (Figure 11). Dose response curves for compounds 
1989, 1990, 1991, 1993, 1994, and 1995 (Figure 12), revealed that compounds 1995 and 
1989 had the lowest IC50 values at 0.602 and 0.604 µM. Whereas the other analogs had 
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higher IC50 values than any of the original compounds on which they were based (Table 





Figure 11. Dose responses of compounds 4, 22, and 59 on TEAD reporter assay. 
Dose response curves for compounds 4, 22, and 59 were obtained as a measurement of 
fold-change of firefly: renilla activity using the TEAD reporter assay. Nonlinear 
regression curves were calculated using 4 parameters with variable slope on GraphPad 
Prism 8 and IC50 values were determined based on curves. Data for individual 





Figure 12. Dose responses of analog compounds on TEAD reporter assay. Dose 
response curves for the analog compounds were obtained as a measurement of fold-
change of firefly: renilla activity using the TEAD reporter assay. Nonlinear regression 
curves were calculated using 4 parameters with variable slope on GraphPad Prism 8 and 
IC50 values were determined based on curves. Data for individual concentrations of 








3.5   Validation of TEAD reporter inhibition with endogenous CTGF measurements  
 
The impact of compounds on endogenous TEAD activity were validated by 
measuring their effects on the levels of endogenous CTGF transcript.  Total mRNA was 
extracted from HeLa cells treated with 20 uM of compound or vehicle for 24 hours. The 
Relative levels of the CTGF transcript as well as 18S rRNA for normalization were then 
measured by Quantitative (q) Real-Time (RT) Polymerase Chain Reaction (PCR). CTGF 
levels in cells treated with compound 1993 were nearly 80 % lower than cells treated 
with DMSO, compound 4 caused a 60% decrease, and compound 22, 1989, and 1994 all 
had about a 50% decrease (Figure 13). However, compound no decrease in the 
transcription of endogenous CTGF was observed in cells treated with 59. This suggests 
that compound 59 inhibited the TEAD reporter assay in a TEAD independent manner. 
All intracellular assay data for compounds 4, 22, 59, and the analogs are summarized in 









Figure 13. Validation of the ability of compounds to inhibit endogenous 
YAP1/TEAD activity.  CTGF mRNA was measured through qRT-PCR in HeLa cells 
treated with DMSO and 20 uM of compounds. Values were normalized to 18S rRNA in 
the samples, N=4 (a). CTGF mRNA fold change was plotted against TEAD reporter 











































4 1.74 30.3% 0.447 
22 1.08 71.8% 0.546 
59 2.80 56.6% 1.13 
1989 4.48 41.3% 0.443 
1990 2.82 43.9% 0.948 
1991 N/A 57.8% 1.12 
1993 N/A 38.2% 0.227 
1994 N/A 51.9% 0.786 
1995 0.602 45.5% 1.47 
 
Table 1. Summary of intracellular assay data. IC50 values reported from TEAD 
reporter dose response curves, the highest observed inhibitions seen in TEAD reporter 
dose response curves, and CTGF mRNA fold change data for each compound.   
 
3.6   Cell growth of PKD cells treated with compound 22 
 In collaboration with the Bacallao Lab, the effects of compound 22 were 
determined on the growth of autosomal dominant polycystic kidney (ADPKD) cells, 
healthy kidney cells from and ADPKD patient (adjacent ADPKD), and normal kidney 
cells treated. While compound 22 inhibited the growth of PKD cells by 20 percent, it had 
no effect on the growth of normal kidney cells or matched normal adjacent cells taken 
from an ADPKD patient (Figure 14). Compound 22 may therefore hold promise as the 
basis for a PKD therapeutic because it prevents the growth of ADPKD cells but not 




Figure 14. Metabolic effects of compound 22 on ADPKD cells. Cell growth of normal 
kidney, autosomal dominant polycystic kidney disease (ADPKD), and adjacent 
autosomal dominant polycystic kidney disease cells treated with 0.9 and 20 uM 
compound 22 for 36 hours were measured through an MTT assay and normalized to cells 





CHAPTER FOUR: BIOCHEMICAL RESULTS  
 
4.1   Validation of the identity and purity of compounds acquired from AtomWise 
The purity and identify of 16 compounds with the greatest effect on the TEAD 
reporter were validated by HPLC and LC-MS (performed by Dr. Steven Johnson and 
Mckayla Stevens, IUSM). The results from these analyses are summarized in Table 2 
alongside their expected masses. The purity of compounds 4, 22, and 59, were all > 97%, 
and the masses of compounds 4 and 22 matched expected values. However, the mass 
measured for compound 59 did not match the expected value. Compound 59 was 
consequently re-synthesized by Dr. Johnson and shown to have the same “incorrect” 
mass by LC-MS. The lack of a good ionizing group on compound 59 may prevent it from 
flying well in the MS. Consequently, compound 59 was analyzed by both H1 NMR and 
C13 NMR, which both supported a correct structure. 
 
Table 2. Validation of identity and purity of compounds through mass spectrometry 
and HPLC. The identity and purity of compounds received from AtomWise, Inc were 
Compound HPLC-1 (Acetonitrile) HPLC-2 (Methanol) MS Obtained MS Expected 
4 99% 98% 408.9 409.0 
7 >99% 99% 465.9 429.9 
10 >99% >99% 405.1 405.2 
18 96% 96% 446.0 446.1 
22 97% >99% 365.0 365.1 
24 87% 86% 445.1 445.2 
25 >99% >99% 378.0 378.1 
27 97% 99% 407.0 407.1 
53 98% >99% 406.0 406.1 
54 78% 78% 442.1 442.1 
58 99% 98% 400.1 400.1 
59 >99% >99% 461.0 429.1 
61 68% 98% 440.0 440.1 
62 >99% >99% 408.9 409.0 
73 92% 96% 401.0 401.2 
78 >99% >99% 371.1 371.1 
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validated through HPLC with methanol and acetonitrile as solvents and mass 
spectrometry.  
 
4.2   TEAD2 expression and purification  
 Initial attempts to purify TEAD employed a Yeast expression system to 
potentially increase the amount of TEAD with palmitoylation. After several attempts of 
expressing and purifying TEAD in yeast, we became aware that the strain provided by 
our yeast collaborator did not contain recombinant TEAD. All consequent efforts to 
purify TEAD utilized E. coli for expression.  
 A 6x His-tagged TEAD2 cDNA (obtained from Guo at University of Texas 
Southwestern) was obtained as this construct was used to express proteins that were 
consequently used to obtain x-ray crystallography structures. Purified TEAD2 was auto-
palmitoylated by incubation with palmitoyl-CoA. Quadrupole-time of flight mass 
spectroscopy (QToF) (completed by Dr. Georgiadis) confirmed that a majority of TEAD2 
was palmitoylated. As seen in Figure 15, non-palmitoylated TEAD2 with a mass of 
27321.9 g/mol and palmitoylated TEAD2 at a mass of 27560.5 g/mol are both highly 
represented. Specifically, 31.5% of the TEAD2 was palmitoylated before incubation with 
palmitoyl-COA, whereas 63.8% of the TEAD2 was palmitoylated after incubation with 







Figure 15. Mass spectrometry analysis of TEAD2 treated with palmitoyl-CoA. QToF 
was used to validate that TEAD2 was expressed and purified and to determine the 
amount of unpalmitoylated and palmitoylated TEAD2 in both the unmodified sample (a) 
and the sample with added Palmitoyl CoA (b). Unpalmitoylated TEAD2 has a mass of 


















27321.9 1068611.39 68.5% 27321.9 275901.77 36.2% 
27560.5 491943.57 31.5% 27560.5 486977.91 63.8% 
 
Table 3. Mass spectrometry analysis of TEAD2 treated with palmitoyl-CoA. The 
abundancies of unpalmitoylated TEAD2 (mass of 27332.9 g/mol) and palmitoylated 
TEAD2 (mass of 27560.5 g/mol) were determined for the purified TEAD2 before and 




4.3   Fluorescence polarization 
 Two YAP1 peptides were synthesized (Dr. Mark Jarosinski) consisting of the 
residues 58-74 (Peptide#1) or residues 61-99 (Peptide#2) from full-length YAP1. 
Peptide#1 contains the residues that make up the alpha-helical region of YAP1 that binds 
to TEAD.  Peptide#2 contains all of the residues in the three interfaces that bind to 
TEAD. Fractions of both peptides were coupled to 6-carboxyfluorescein (5(6)-FAM) at 
their N-termini for use in fluorescence polarization studies.  
The binding of these two YAP1 peptides to purified TEAD were then measured 
by fluorescence polarization based studies. We first investigated whether the 
palmitoylation of TEAD2 affects its binding to the YAP1 peptides. While non-
palmitoylated TEAD2 had no detectable binding to Peptide#1, it bound to peptide #2 
with a similar Kd as palmitoylated TEAD2 (Figure 16). The binding of fluorescently 
labeled peptide #1 to palmitoylated TEAD was then measured in backgrounds of 
increasing concentrations of unlabeled peptide #1 (Figure 17). The small decrease in 
fluorescence polarization observed at higher concentration of unlabeled peptide suggests 
that changes in fluorescence polarization values reflects some degree of specific binding 
of YAP1 to TEAD. The impact of increasing concentrations of compounds 4, 22, 59, and 
78 on the binding of fluorescently labeled YAP1 peptide #2 to TEAD were then 
completed (Figure 18). While compound #4 had no effect even at 30 uM, a modest 
decrease in YAP1 binding to TEAD was observed in the presence of 1 to 30 µM of 
compounds 4, 22 and 59. Similar dose response curves for compounds 1989, 1990, 1991, 
1993, 1994, and 1995 revealed that compounds 1991 and 1994 at 1- 30 µM showed 
significant reduction of YAP1 binding to TEAD (Figure 19). In summary, compounds 
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22, 1991, and 1994 have predicted IC50 values of 9.07, 1.75, and 6.66 µM, while all other 
compounds had little to no effect.   
 While these data have made important steps for biochemically measuring the 
ability of compounds to inhibit YAP1 binding to TEAD, there are still several 
experimental issues to be resolved. Important accomplishments include the development 
of an optimized protocol to purify TEAD as well as preparation of several milligrams of 
highly purified TEAD. Further, we have designed and synthesized Peptide#2, which by 
fluorescence polarization appears to bind to TEAD with submicromolar affinity.  
However, many issues must be resolved to complete these studies.  This includes 
increasing the dynamic range over which FP values change in response to increasing 
concentrations of YAP1 peptide #2.  While, a range of 0.1 units is observed, a range of 
0.25 units from roughly 0.05 to 0.3 is generally found in similar types of studies [53]. 
This may be improved by increasing the amount of TEAD in these assays from 1 µM to 3 
µM.  Further, assays examining the ability of compounds to compete with YAP1 for 
binding to TEAD had low precision and the inhibition of YAP1 binding was modest.  
These issues may be improved by using preparations of TEAD that are more pure and or 
stable.  Also, the fluorophore on the YAP1 peptides may have suffered from 
photobleaching.  This may be improved by making new solutions of peptide from 
powdered stocks and by preparing the assays for fluorescence polarization under low 








Figure 16. Binding effects of YAP1 to TEAD2 upon palmitoylation of TEAD2. 
Fluorescence polarization was used to analyze the binding of peptide #1 (a) and peptide 
#2 (b) unmodified TEAD2 and TEAD2 treated with palmitoyl-CoA. 10 nM of 
fluorescently labeled peptide was used with increasing concentrations of palmitoylated 




Figure 17. Competitive binding curve of YAP1 fluorescently labeled peptide #1 and 
unlabeled peptide #1 with TEAD2. A competitive binding curve using 10 nM 
fluorescently labeled Peptide#1 and increasing concentrations of unlabeled peptide #1 




Figure 18. Effects of compounds 4, 22, 59, and 78 on peptide #2 binding with 
TEAD2. Dose responses of compounds 4, 22, 59, and 78 were completed by 
fluorescence polarization using 1 uM of palmitoylated TEAD2 and 10 nM fluorescent 
peptide #2. GraphPad Prism8 was used to fit curves and determine IC50 values using 4 






























































Figure 19. Effects of analog compounds on peptide #2 binding with TEAD2. Dose 
responses of compounds 1989, 1990, 1991, 1993, 1994, and 1995 were completed by 
fluorescence polarization using 1 uM of palmitoylated TEAD2 and 10 nM of fluorescent 
peptide #2. GraphPad Prism8 was used to fit curves and determine IC50 values using 4 













































































CHAPTER FIVE: DISCUSSION 
 
5.1   Compounds 22 and 59 as YAP1:TEAD inhibitors  
Increased levels of YAP1 have been linked to cellular proliferation, de-
differentiation and cell survival to drive tumor progression and spreading. By preventing 
the binding of the coactivator YAP1 to the transcription factor TEADs, the initiation and 
metastasis of cancer could be prevented. Several studies report small molecules that 
inhibit the binding of YAP1 to TEAD but none of these reagents have been shown to 
possess high specificity and promising anti-tumor action. This work has shown that 
compounds 22 and 59 both inhibit TEAD dependent transcription and cell growth in 
multiple cancer cell lines making them promising inhibitors of YAP1-TEAD interactions. 
Further, preliminary data suggests that several of the compounds physically inhibits the 
binding of YAP1 to TEAD. The relatedness of these compounds opens up the potential 
for rational design of improved compounds that may lead to the discovery of a potent 
YAP1:TEAD inhibitor.  
 
5.2   Compound 22 as a potential PKD therapeutic 
 ADPKD cells that were treated with compound 22 for 24 hours exhibited a 20% 
decrease in cell growth, while adjacent ADPKD cells and healthy kidney cells saw no 
decrease in cell growth when treated with compound 22 for the same amount of time. 
This is an exciting result, suggesting that the ADPKD cells are growing in a 
YAP1/TEAD dependent manner and the healthy cells, even in an ADPKD patient, are 
not affected with treatment of compound 22. A complete dose response curve will need 
to be completed with compound 22 and ADPKD cells, but the fact that the ADPKD cells 
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had 20% growth inhibition when treated with both 0.9 uM and 20 uM of compound 22 
suggests that 20% inhibition may be the greatest inhibition that can be seen through a 
YAP1:TEAD inhibitor. This may be because only a fraction of the kidney cells of an 
ADPKD patient actually possess the Pkd1 mutation that leads to accumulation of nuclear 
YAP1. This means only a small portion of the cells are growing due to increased nuclear 
YAP1, so seeing growth inhibition even at 20% is promising.  
 
5.3   Sulfonamides as potential YAP1:TEAD binding inhibitors  
 The initial screen of compounds received from AtomWise, Inc revealed that the 
compounds that caused the largest decrease in TEAD dependent transcription are all 
sulfonamides. Sulfonamides have been widely studied and used as antimalarial and 
antibacterial agents. Because sulfonamides have been used for treatment of human 
disease, they are intriguing in research due to sufficient absorption, distribution, 
metabolism, and excretion (ADME) properties that have been seen in several other 
sulfonamides. Sulfonamides are also easy to synthesize, allowing for the creation of a 
large library of sulfonamides to be tested. This work touched on the possibilities of SAR 
by synthesizing and analyzing the activity of six chemical analogs of the inhibitors 
initially screened. This expanded on the moieties of the compounds initially observed to 
have the largest effects on TEAD dependent transcription, including compounds 4, 22, 
and 59, which all had amide bond containing rings. Because the initial assay was 
completed intracellularly, we know that these compounds are permeable to the cell 
membrane. This also suggests that these compounds are permeable to the nuclear 
membrane because it is having an effect on TEAD dependent transcription, making these 
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sulfonamide compounds even more interesting. Further SAR work can be done by 
making a larger library of compounds, adjusting the substituents and moieties based on 
data obtained on the activity of the compounds. 
 
5.4   The role of palmitoylation of TEAD2 in YAP1:TEAD interactions  
To date, it has been controversial whether the palmitoylation of TEAD is 
necessary for its binding ability and function. Fluorescence polarization data in this work 
suggests that the palmitoylation of TEAD2 may play a role in the stability and structure 
of the alpha helical region of the TEAD2:YAP1 binding domain that contains the 
hydrophobic pocket, which interacts with the YAP Phe-69. However, the 38 amino acid 
peptide that interacts with the alpha helical, beta strand, and omega loop of TEAD2, 
bound similarly to palmitoylated and unmodified TEAD2. In fact, unmodified TEAD2 
seems to bind with a slightly higher affinity to the longer peptide. However, this could be 
due to the palmitoylated TEAD2 being less pure. On the other hand, the short peptide 
appears to only bind the palmitoylated TEAD2 and does not bind unmodified TEAD2. 
This data suggests that the palmitoylation within the deep hydrophobic pocket of TEAD2 
plays an important role in the folding and stability of the region within TEAD that binds 
to the alpha helical region of YAP1.  
 
5.5   Future Work with YAP:TEAD inhibitors  
This work has shown that compound 22 is a promising inhibitor of intracellular 
YAP-TEAD and that it possess a modest ability to disrupt YAP1 binding to TEAD in a 
purified system. While the FP data is preliminary, compounds 1991 and 1994 were 
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actually more effective inhibitors of YAP1 binding to TEAD than either 22 or 59.  
However, these analogs had a poorer ability to disrupt the intracellular activation of 
TEAD by YAP1.  Consequently, additional FP experiments will be needed to fully 
characterize the biochemical potential of these compounds to disrupt YAP1 binding to 
TEAD. Because a decrease in binding to the fluorescently labeled peptide was not seen in 
the presence of increasing concentrations of unlabeled peptide, the fluorescent 
polarization assay used in this work is not working properly. It is possible that the FAM 
fluorophore is interacting with TEAD2 not in the protein binding domain. In the future, a 
new fluorophore could be attached to the peptide to see if a better competitive binding 
curve can be seen.  Future work using x-ray crystallography could also show how these 
compounds bind to TEAD2 which will enable further structure-activity relationships 
(SAR). A long-term goal would be the development of compounds that have efficacy in 
animal models of certain cancers.  This would then lay the groundwork for moving these 
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